Article Download
Overcoming the High Cost of Biosimilar Production
Despite being lower-cost alternatives to traditional biologics, production of biosimilar monoclonal antibodies (mAbs) can still be complex and costly due significantly to downstream processing. In this case study, learn how a combined ion exchange and mixed-mode purification workflow can perform as well as traditional Protein A solutions but at lower cost.
Read this case study to learn how:
- Using a strong cation exchange resin for the affinity capture step can help minimize purification costs and overcome the limitations of Protein A capture
- A combined ion exchange and mixed-mode purification workflow can help achieve greater product purity and increase dynamic binding capacity
- Adopting alternative purification workflow models can improve process efficiency and economics of biosimilar production
Download the Article
Share a little information with us to access the entire article now.
Content you'll also find interesting
Recommended Features
-
Image
Selecting Chromatography Resins for Antibody Purification
Learn how to select optimal chromatography resins for monoclonal antibody (mAb) purification with our handy guide.
-
Image
Using Droplet Digital™ PCR to Detect Mycoplasma Contamination
Optimize your antibody purification strategy with our antibody purification guide for selecting resins ideal for capture, intermediate, and polish.
-
Image
Monoclonal Antibody Purification Guide
Optimize your antibody purification strategy with our antibody purification guide for selecting resins ideal for capture, intermediate, and polish.
